Molecure S.A. (FRA:1B1)

Germany flag Germany · Delayed Price · Currency is EUR
1.664
+0.042 (2.59%)
Last updated: Dec 5, 2025, 8:18 AM CET
-29.49%
Market Cap 35.14M
Revenue (ttm) 1.37M
Net Income (ttm) -5.72M
Shares Out n/a
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 1.664
Previous Close 1.622
Day's Range 1.664 - 1.664
52-Week Range 1.216 - 2.475
Beta n/a
RSI 64.99
Earnings Date Mar 26, 2026

About Molecure

Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-4... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 102
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1B1
Full Company Profile

Financial Performance

In 2024, Molecure's revenue was 2.92 million, a decrease of -20.08% compared to the previous year's 3.65 million. Losses were -31.29 million, 10.3% more than in 2023.

Financial numbers in PLN Financial Statements

News

There is no news available yet.